accord
world
health
organ
latest
report
middl
east
respiratori
syndrom
coronaviru
merscov
caus
laboratoryconfirm
infect
death
mortal
rate
countri
sinc
viru
first
isol
saudi
arabia
septemb
http
wwwwhointemergenciesmerscoven
although
case
closelyrel
sever
acut
respiratori
syndrom
coronaviru
sarscov
report
sinc
incid
merscov
infect
number
affect
countri
continu
increas
epidemiolog
trend
indic
prevent
potenti
epidem
spread
merscov
like
long
tough
battl
unfortun
clinicallyapprov
antivir
monoclon
antibodi
mab
small
molecul
drug
vaccin
merscov
avail
preclin
anim
model
mimic
human
pathogenesi
merscov
infect
urgent
need
develop
vaccin
therapi
classif
merscov
biosafeti
level
three
agent
addit
hurdl
progress
area
sinc
emerg
merscov
sever
anim
speci
evalu
potenti
model
includ
wildtyp
mice
mice
defici
innat
immun
syrian
hamster
ferret
nonhuman
primat
nhp
two
nhp
rhesu
macaqu
marmoset
found
suscept
merscov
infect
speci
includ
mice
natur
nonpermiss
infect
although
human
identifi
receptor
merscov
mediat
infect
mous
function
respect
mice
adenovir
transduc
could
transient
infect
merscov
develop
fatal
mer
diseas
moreov
tg
mice
express
control
either
cytokeratin
promot
ubiquit
promot
suscept
merscov
infect
develop
fatal
diseas
also
develop
unrel
lethal
enceph
two
knockin
ki
mice
replac
use
could
infect
hightit
merscov
isol
suscept
mouseadapt
merscov
strain
sinc
central
normal
glucos
homeostasi
play
import
role
immun
alter
sequenc
may
disrupt
function
neutral
antivir
mab
promis
candid
treatment
prevent
merscov
infect
sever
highli
potent
mous
human
human
neutral
mab
target
receptorbind
domain
rbd
spike
protein
report
antivir
compound
prophylact
vaccin
also
develop
vaccin
therapeut
agent
typic
evalu
vitro
system
use
merscov
pseudovirus
howev
efficaci
must
eventu
confirm
vivo
use
suitabl
anim
model
sever
tg
ki
mice
suscept
merscov
avail
challeng
experi
condit
done
evalu
potenti
therapeut
vaccin
studi
establish
novel
ki
mous
insert
fulllength
gene
mous
genom
locu
use
constitut
ubiquit
gene
express
use
gene
edit
technolog
mous
term
display
sever
lung
diseas
relat
acut
respiratori
symptom
ard
well
central
nervou
system
cn
involv
infect
authent
merscov
clinic
isol
low
dose
moreov
hightit
merscov
pseudoviru
could
also
product
infect
mice
effect
compar
follow
authent
infect
wildtyp
mice
geneticallymodifi
mice
suppli
institut
laboratori
anim
resourc
nation
institut
food
drug
control
beij
china
studi
perform
complianc
anim
protocol
approv
institut
anim
care
use
committe
nation
institut
food
drug
control
china
food
drug
administr
cfda
beij
china
complianc
guid
care
use
laboratori
anim
nation
academi
press
washington
dc
usa
ed
licens
number
anim
use
certif
issu
scienc
technolog
depart
china
beij
china
syxk
approv
februari
construct
target
vector
cdna
encod
also
known
link
red
fluoresc
protein
tdtomato
intern
ribosom
entri
site
ire
sequenc
insert
homolog
recombin
sequenc
locu
target
vector
sgrna
specif
locu
mrna
microinject
zygot
subsequ
implant
pseudopregn
mice
offspr
genotyp
use
primer
expect
amplicon
size
use
primer
genotypeposit
founder
backcross
mice
produc
gener
tail
tip
four
mice
subject
southern
blot
confirm
correct
insert
replicationincompet
hiv
virion
pseudotyp
merscov
protein
human
betacoronaviru
express
firefli
luciferas
fluc
gener
previous
describ
merscov
protein
sequenc
codon
optim
homo
sapien
genewiz
suzhou
china
clone
express
vector
yield
briefli
human
embryon
kidney
hek
cell
atcc
cotransfect
lentivir
vector
use
variou
transfect
reagent
includ
lipofectamin
invitrogen
carlsbad
ca
usa
lipofectamin
invitrogen
usa
polyethylenimin
alfa
aesar
lancashir
uk
neofect
vigofect
vigor
biotechnolog
beij
china
turbofect
thermo
scientif
waltham
usa
incub
h
cultur
supernat
centrifug
g
min
filter
filter
concentr
ultrafiltr
devic
millipor
boston
usa
experi
involv
pseudotyp
merscov
perform
conduct
highthroughput
vitro
neutral
assay
optim
dose
merscov
pseudoviru
incub
mab
h
mixtur
ad
human
hepatoma
cell
fengh
bio
inc
changsha
china
cell
type
plate
incub
h
infect
merscov
pseudovirus
determin
measur
bioluminesc
describ
previous
recombin
extracellular
domain
merscov
spike
protein
human
betacoronaviru
recombin
rbd
purchas
sino
biolog
inc
beij
china
phage
librari
construct
antibodi
select
carri
describ
sixweekold
femal
balbc
mice
immun
intraperiton
ip
recombin
protein
rna
extract
spleen
cell
use
construct
phagedisplay
antibodi
librari
recombin
rbd
protein
use
screen
antibodi
four
round
pan
antibodi
specif
recogn
protein
obtain
variabl
region
light
heavi
chain
antibodi
fuse
mous
kappa
constant
region
use
pcr
clone
transient
express
vector
suspens
cell
transfect
light
chain
heavi
chain
express
vector
recombin
mous
mab
purifi
cultur
supernat
use
protein
affin
chromatographi
posit
control
prepar
provid
prof
tianlei
ying
peptid
inhibitor
merscov
provid
prof
shibo
jiang
variabl
region
light
heavi
chain
mous
antibodi
align
human
germlin
gene
homolog
human
framework
chosen
human
murin
sequenc
preserv
key
residu
maintain
structur
stabil
codonoptim
lightchain
heavychain
variabl
region
sequenc
synthes
clone
express
vector
contain
kappa
constant
region
suspens
cell
transfect
express
vector
encod
light
heavi
chain
express
antibodi
purifi
supernat
use
protein
affin
chromatographi
day
mice
challeng
differ
rout
vari
dose
pseudotyp
merscov
ivislumina
ii
imag
system
xenogen
baltimor
md
usa
use
detect
bioluminesc
describ
previous
prior
measur
luminesc
mice
anesthet
ip
inject
sodium
pentobarbit
mgkg
exposur
time
fluoresc
intens
region
interest
analyz
use
live
imag
softwar
calip
life
scienc
baltimor
md
usa
differ
wavelength
use
detect
pseudoviru
tdtomato
fluoresc
substrat
dluciferin
mgkg
xenogencalip
corp
alameda
ca
usa
inject
ip
imag
conduct
min
later
rel
intens
emit
light
repres
color
rang
red
intens
blue
weak
quantit
present
photon
flux
fourweekold
wildtyp
mice
challeng
authent
merscov
strain
hcovemc
pfu
intranas
rout
bodi
weight
measur
daili
fifth
day
postinfect
pi
mice
sacrif
sampl
collect
time
sacrific
base
consider
human
euthanasia
bodi
weight
loss
exceed
viral
titer
lung
tissu
determin
plaqu
assay
vero
cell
follow
protocol
describ
previous
authent
merscov
strain
hcovemc
maintain
test
facil
facil
institut
laboratori
anim
scienc
cam
pumc
beij
china
strict
use
person
protect
equip
describ
previous
tissu
dissect
immedi
immers
stabil
reagent
invitrogen
usa
store
total
rna
extract
individu
tissu
use
trizol
quantifi
use
spectrophotomet
wavelength
nm
random
hexam
use
prime
reversetranscript
reaction
use
revers
transcript
rt
pcr
kit
contain
sybr
green
dye
takara
shiga
japan
realtim
quantit
pcr
rtqpcr
perform
use
light
cycler
realtim
pcr
system
roch
indianapoli
usa
reaction
perform
triplic
rel
express
level
determin
use
primer
normal
express
gapdh
glyceraldehyd
dehydrogenas
viral
load
quantifi
use
primer
taqman
probe
data
present
log
viral
rna
copiesgapdh
copi
mous
tissu
homogen
ripa
lysi
buffer
mm
trishcl
ph
contain
mm
nacl
mm
edta
sd
supplement
proteinas
inhibitor
pi
roch
basel
switzerland
denatur
protein
lysat
separ
use
sdspage
gel
transfer
mous
monoclon
antibodi
dilut
origen
rockvil
md
usa
antigapdh
antibodi
abcam
cambridg
uk
ad
follow
horseradish
peroxidas
hrp
conjug
antimous
igg
santa
cruz
biotechnolog
santa
cruz
ca
usa
immobilon
western
chemiluminesc
hrp
substrat
kit
millipor
corpor
billerica
usa
use
develop
mous
tissu
fix
neutralbuff
formalin
embed
paraffin
section
thick
tissu
section
stain
hematoxylin
eosin
histopatholog
examin
immunohistochemistri
ihc
tissu
section
rehydr
incub
coplin
jar
fill
citra
buffer
ph
microwav
oven
min
cool
room
temperatur
min
block
normal
goat
serum
min
section
incub
overnight
either
rabbit
produc
phage
display
specif
receptorbind
domain
merscov
kindli
provid
beij
wantai
biolog
pharmaci
enterpris
co
ltd
beij
china
normal
goat
serum
control
section
wash
pb
incub
hrpconjug
goatantirabbit
secondari
antibodi
zhongshan
golden
bridg
biocompani
beij
china
min
room
temperatur
follow
develop
zhongshan
golden
bridg
biocompani
beij
china
counterstain
hematoxylin
sampl
size
group
calcul
base
anticip
effect
size
yield
statist
signific
differ
inhibit
rate
mab
calcul
use
follow
formula
valu
posit
mab
treatment
group
valu
posit
group
valu
repres
either
fluoresc
deriv
pseudoviru
infect
authent
viral
titer
lung
tissu
data
analyz
use
spss
ver
ibm
armonk
ny
usa
graphpad
prism
graphpad
softwar
san
diego
ca
usa
result
experi
present
mean
plu
standard
deviat
sd
standard
error
mean
sem
student
ttest
use
assess
differ
group
dunnett
test
perform
multipl
comparison
p
valu
less
consid
statist
signific
ki
mous
gener
insert
fulllength
gene
locu
shown
safe
harbor
develop
genet
stabl
ki
mous
line
express
driven
splice
acceptor
allow
ubiquit
express
control
promot
tdtomato
gene
insert
downstream
intern
ribosom
entri
site
allow
coexpress
tdtomato
poli
sequenc
woodchuck
hepat
viru
posttranscript
regulatori
element
wpre
ad
enhanc
mrna
stabil
translat
effici
figur
target
vector
along
subgenom
rna
sgrna
mrna
inject
zygot
mice
success
insert
nine
offspr
posit
confirm
southern
blot
result
five
mice
present
figur
one
male
founder
one
femal
founder
die
wean
two
founder
emaci
mate
five
founder
backcross
mice
two
mate
produc
offspr
tail
tip
mice
subject
pcr
genotyp
figur
southern
blot
confirm
correct
insert
homozyg
mice
term
rosa
abbrevi
signific
express
could
detect
rtpcr
mous
tissu
test
figur
express
detect
wildtyp
mice
western
blot
lung
brain
tissu
confirm
express
figur
unlik
tg
mice
show
highestlevel
express
heart
brain
mice
highest
express
lung
profit
insert
tdtomato
downstream
global
express
pattern
examin
visual
figur
via
bioluminesc
imag
bli
sinc
liver
intestin
lung
bigger
volum
brighter
imag
organ
test
whether
mice
could
support
effici
infect
replic
merscov
wildtyp
mice
infect
merscov
clinic
strain
hcovemc
dose
pfu
bodyweight
wildtyp
mice
increas
approxim
figur
day
pi
mice
experienc
signific
weight
loss
day
pi
mice
lost
least
bodyweight
meet
typic
cutoff
use
human
euthanasia
criteria
two
mice
lost
bodi
weight
day
pi
viral
titer
lung
mice
measur
approxim
pfu
sat
day
pi
viru
detect
lung
wildtyp
mice
figur
mean
differ
log
pfu
ci
log
pfu
although
weight
loss
viral
load
provid
import
measur
mous
suscept
paramet
directli
reflect
patholog
chang
therefor
lung
brain
liver
kidney
collect
infect
mice
subject
histopatholog
analysi
ihc
figur
quantit
analysi
patholog
score
symptom
mice
significantli
differ
compar
wildtyp
mice
figur
associ
patholog
chang
signific
viral
load
detect
lung
figur
cerebellum
cerebr
ganglia
cerebrum
mice
perivascular
gliosi
observ
figur
supplementari
figur
accompani
viru
detect
organ
figur
obviou
lesion
observ
liver
kidney
figur
viru
detect
organ
figur
despit
fact
merscovinfect
patient
acut
nephriti
report
contrast
correspond
organ
wildtyp
mice
minim
patholog
chang
observ
viru
could
detect
figur
result
indic
mice
permiss
infect
authent
merscov
infect
accompani
sever
diseas
symptom
similar
merscovinfect
human
patient
next
evalu
effect
neutral
mabon
mice
infect
authent
viru
end
human
mab
gener
phage
display
method
administ
intraven
iv
ata
singl
dose
either
mgkg
mgkg
h
infect
hcovemc
pfu
administr
significantli
decreas
viral
titer
lung
log
pfu
log
pfu
log
pfu
mgkg
mgkg
group
respect
figur
reduc
weight
loss
dosedepend
manner
tabl
viral
titer
higher
mab
dose
group
limit
detect
averag
inhibit
rate
authent
viru
mgkg
mab
mgkg
mab
respect
notabl
complet
ablat
viral
load
lung
two
four
mice
low
high
dose
mab
group
figur
ihc
result
confirm
lower
viral
load
lung
mabtreat
mice
figur
reduct
viral
load
cerebellum
less
clear
figur
addit
treatment
mab
allevi
symptom
lung
brain
figur
degener
necrosi
bronchial
epitheli
cell
improv
significantli
treat
anim
figur
p
result
indic
human
mab
promis
antivir
agent
prevent
merscov
infect
importantli
result
also
impli
mous
could
effect
model
evalu
antivir
agent
merscov
vivo
zhao
et
al
report
merscov
pseudoviru
allow
singleround
infect
sever
cell
line
express
howev
despit
use
sever
proven
method
first
fail
infect
mice
otherwis
permiss
infect
authent
viru
use
pseudotyp
viru
first
attribut
failur
low
pseudoviru
titer
therefor
optim
paramet
pseudoviru
product
supplementari
figur
final
pseudoviru
titer
supplementari
figur
obtain
pseudoviru
titrat
mice
anim
infecti
dose
determin
viatheintrathorac
rout
establish
vitro
neutral
assay
cellular
tropism
phivmerssfluc
test
variou
cell
line
cell
line
test
permiss
phivmerssfluc
infect
cell
show
highest
infect
effici
supplementari
figur
demonstr
wide
cellular
tropism
pseudotyp
virion
result
cell
line
chosen
establish
chemiluminescencebas
highthroughput
antibodi
neutral
assay
assay
display
good
sensit
specif
sinc
ip
infect
rout
effici
pseudotyp
ebola
viru
model
group
mice
administ
pseudotyp
viru
ip
mice
anaesthet
observ
bli
system
variou
day
pi
bioluminesc
transgeneencod
fluc
report
first
observ
day
pi
abdomen
close
inject
site
figur
bioluminesc
spread
thorac
caviti
day
pi
bioluminesc
reach
peak
intens
gradual
weaken
day
pi
figur
identifi
site
infect
mice
dissect
organ
observ
day
peak
infect
figur
show
thymu
liver
spleen
kidney
lung
muscl
among
organ
tissu
infect
pseudoviru
higher
pseudoviruscopi
number
detect
organ
figur
illustr
mice
could
effici
infect
pseudoviru
sinc
merscov
infect
mainli
caus
clinic
ard
primari
site
infect
respiratori
tract
therefor
maxim
infect
respiratori
tract
infect
mice
via
rout
liveanim
imag
show
infect
mainli
local
chest
maxim
infect
occur
day
pi
use
rout
major
infect
organ
thymu
heart
lung
figur
uniform
infect
profil
observ
mice
indic
challeng
advantag
ip
challeng
iv
challeng
also
attempt
result
product
infect
test
influenc
anim
age
suscept
infect
mice
inocul
pseudoviru
younger
older
mice
could
infect
younger
mice
suscept
figur
f
report
previous
fluoresc
intens
viru
copi
number
tissu
strongli
correl
suggest
fluoresc
intens
could
use
indic
pseudoviru
infect
pseudoviru
infect
caus
histopatholog
chang
indic
tool
safe
mice
figur
notabl
bli
visual
confirm
ihc
found
pseudoviru
tend
infect
bronchi
figur
tropism
share
authent
viru
figur
compar
infect
profil
mice
infect
pseudotyp
authent
merscov
tabl
lung
major
infect
organ
type
viru
figur
b
pulmonari
bronchial
epitheli
cell
common
site
infect
figur
lung
tissu
tropism
also
support
measur
pseudoviru
copi
number
figur
authent
viru
titer
figur
dose
convers
pseudoviru
authent
viru
shown
figur
authent
viru
observ
cn
figur
figur
infect
mice
interestingli
observ
pseudoviru
could
also
enter
cn
detect
qrtpcr
bli
brain
pseudoviru
cross
bloodbrain
barrier
requir
investig
monoclon
antibodi
provid
robust
strategi
protect
infect
caus
merscov
vitro
pseudoviru
neutral
assay
use
tool
test
efficaci
mab
therefor
vitro
efficaci
human
neutral
mab
protect
mice
infect
pseudotyp
merscov
assess
comparison
vitro
efficaci
fulli
human
neutral
mab
protect
mice
infect
also
determin
inhibitori
concentr
mab
determin
ngml
respect
repres
high
vitro
inhibitori
activ
mab
administ
itto
mice
dose
mgmous
prior
challeng
pseudoviru
day
day
pi
peak
signal
could
detect
bli
imag
whole
bodi
organ
obtain
mab
demonstr
strong
protect
efficaci
shown
figur
ablat
pseudoviru
infect
administ
either
ip
rout
figur
b
pseudoviru
report
signal
mice
administ
also
decreas
significantli
whole
bodi
well
lung
thymu
figur
e
f
p
next
dose
convers
pseudoviru
authent
viru
calcul
order
establish
safeti
profil
three
group
mice
challeng
differ
dose
pseudoviru
either
without
treatment
mab
mgkg
h
prior
challeng
bli
mice
perform
day
pi
inhibit
rate
calcul
shown
figur
mice
challeng
pfu
authent
viru
inhibit
rate
mgkg
inhibit
rate
curv
pseudoviru
infect
deduc
pseudoviru
dose
correspond
inhibit
pseudoviru
equival
pfu
authent
viru
assum
quantit
paramet
would
use
screen
antivir
agent
evalu
vaccin
merscov
sinc
mous
provid
suitabl
model
infect
pseudotyp
authent
merscov
pseudoviru
model
conveni
tool
evalu
vivo
efficaci
antimerscov
agent
vaccin
biolog
laboratori
lack
facil
sinc
peptid
deriv
heptad
repeat
hr
merscov
protein
analogu
shown
protect
mice
infect
merscov
strain
investig
whether
could
also
prevent
pseudoviru
infect
mice
test
vitro
inhibitori
effect
cell
line
determin
ngml
order
determin
vivo
protect
effect
mice
administ
peptid
per
mous
min
later
challeng
pseudoviru
use
rout
shown
figur
pseudoviru
infect
clearli
prevent
one
repres
mous
pseudoviru
signal
decreas
level
similar
uninfect
mice
repres
full
protect
figur
b
weak
pseudoviru
signal
detect
lung
thymu
heart
dissect
figur
indic
mous
model
like
previou
anim
model
use
evalu
antivir
peptid
merscov
infect
caus
acut
respiratori
distress
neurolog
syndrom
death
mab
promis
tool
therapeut
prophylact
intervent
pathogen
howev
dearth
clinicallyeffect
vaccin
therapeut
compel
us
develop
novel
anim
model
could
faith
mimic
characterist
human
diseas
enabl
better
evalu
potenti
vaccin
therapi
respiratori
diseas
ard
acut
renal
failur
main
symptom
merscov
infect
although
patient
fatal
diseas
cn
report
therefor
anim
model
merscov
diseas
recapitul
patholog
characterist
respiratori
tract
cn
support
highlevel
viru
replic
vivo
exhibit
lung
patholog
associ
ard
requir
moreov
anim
model
must
econom
genet
stabl
show
reproduc
result
mouseadapt
viral
strain
wide
use
establish
infect
model
wherev
possibl
clinic
isol
use
challeng
experi
http
wwwgryphonscientificcomgainoffunct
target
transgen
specif
site
mous
genom
mani
advantag
random
insert
typic
use
transgen
method
two
mice
creat
gene
edit
recent
report
mice
gene
either
replac
mutat
function
disrupt
sinc
endow
differ
biolog
activ
immun
glycometabol
compar
establish
ki
mice
insert
fulllength
human
locu
via
spare
function
notabl
mous
display
unusu
express
profil
transgen
stabli
highli
express
lung
also
express
lesser
extent
brain
organ
figur
reason
express
pattern
might
support
robust
infect
lesion
lung
brain
use
pseudotyp
authent
merscov
reason
insert
safe
harbor
locu
conserv
function
would
appropri
strategi
establish
genet
stabl
anim
model
insert
mean
whether
implic
express
biolog
activ
clear
observ
mice
could
infect
clinic
authent
strain
hcovemc
dose
pfu
infect
caus
diseas
symptom
lung
brain
similar
observ
clinic
patient
infect
mice
experienc
signific
loss
bodi
weight
compar
observ
mice
infect
mouseadapt
strain
higher
viral
titer
previou
report
detect
lung
accompani
diffus
pathogenesi
includ
widen
alveolar
septa
vascular
dilat
hyperemia
perivascular
infiltr
inflammatori
cell
necrosi
bronchial
epitheli
cell
edema
hyalin
membran
format
figur
supplementari
figur
pathophysiolog
find
close
associ
clinic
manifest
infect
uniform
diseas
symptom
signific
differ
observ
ki
wildtyp
mice
reveal
quantit
patholog
score
figur
report
describ
site
merscov
infect
patient
even
though
data
crucial
understand
viral
pathogenesi
cultur
religi
reason
tissu
sampl
made
avail
howev
studi
use
sever
anim
model
help
address
problem
rhesu
macaqu
transient
lower
respiratori
tract
infect
accompani
inflammatori
cell
infiltr
contrast
sever
interstiti
pneumonia
within
filtrat
alveolar
edema
observ
infect
marmoset
research
use
small
anim
model
mous
transduc
vector
express
tg
mous
model
ki
mice
creat
technolog
provid
uncontest
evid
respiratori
system
main
site
merscov
infect
agreement
clinic
manifest
studi
also
show
lung
especi
bronchi
primari
site
infect
pseudotyp
authent
viru
figur
figur
figur
figur
tabl
whether
merscov
abl
infect
nervou
system
remain
controversi
agraw
et
al
report
high
viral
load
brain
necrosi
inflammatori
reaction
observ
ki
mice
infect
mouseadapt
viral
strain
viral
replic
detect
brain
even
challeng
dose
pfu
anim
model
herald
advantag
mimick
clinic
manifest
ard
absenc
cn
complic
howev
even
though
respiratori
infect
ard
common
clinic
symptom
merscov
infect
patient
sever
neurolog
syndrom
includ
confus
coma
ataxia
well
focal
motor
deficit
report
mice
infect
clinic
strain
hcovemc
dose
pfu
viral
load
detect
use
ihc
assay
figur
cerebellum
cerebr
ganglia
cerebrum
associ
viral
load
perivascular
gliosi
indic
inflammatori
reaction
observ
organ
irrespect
mab
administr
mab
ablat
inflamm
figur
phenomena
observ
wildtyp
mice
challeng
manner
sinc
viru
mainli
detect
membran
motor
neuron
reason
dyskinesia
observ
patient
would
also
manifest
mice
addit
studi
assess
possibl
nerv
infect
conduct
viral
load
nervou
system
consid
titrat
pseudotyp
viru
wide
use
mani
pathogen
use
safe
conveni
tool
viral
infect
studi
therapeut
test
pseudoviru
cell
model
popularli
appli
sinc
rel
easi
develop
howev
pseudoviru
anim
model
wide
avail
even
though
extens
potenti
applic
pseudoviru
anim
model
may
difficult
achiev
due
lack
suscept
absenc
suitabl
infecti
pseudovirus
previous
inhibit
assay
base
pseudoviru
cell
model
establish
use
detect
neutral
antibodi
merscov
howev
pseudovirus
fail
infect
mous
shown
particularli
suscept
authent
viru
presum
effect
might
caus
low
pseudoviru
titer
therefor
codon
protein
backbon
plasmid
product
condit
optim
systemat
result
increas
titer
supplementari
figur
final
result
success
infect
mice
challeng
mice
authent
viru
often
administ
rout
advantag
mimick
clinic
respiratori
tract
infect
tri
infect
mice
pseudoviru
rout
unsuccess
failur
might
result
use
less
pseudoviru
inoculum
nasal
drip
dosag
may
suffici
singl
round
infect
found
differ
infect
rout
might
result
differ
biodistribut
pseudoviru
detect
bli
thymu
liver
spleen
kidney
lung
muscl
intestin
mice
infect
via
ip
rout
howev
challeng
via
rout
pseudoviru
observ
thymu
heart
lung
thu
rout
infect
also
effect
pseudoviru
distribut
exampl
viral
load
might
fail
detect
lung
mice
minor
ip
infect
howev
rout
result
uniform
infect
pattern
lung
especi
bronchi
figur
figur
pseudoviru
distribut
pattern
figur
similar
tg
mice
infect
authent
viru
mice
old
week
could
infect
younger
mice
ie
week
old
better
suscept
pseudoviru
infect
caus
patholog
lesion
multipl
organ
indic
model
safe
figur
verifi
potenti
mous
model
evalu
differ
antivir
agent
merscov
test
newli
gener
human
neutral
mab
well
known
merscovneutr
mab
pseudoviru
model
expect
show
outstand
inhibitori
activ
pseudoviru
cell
model
ngml
pseudoviru
mous
model
moreov
mab
also
effect
protect
mice
authent
viru
infect
protect
effect
wellcharacter
peptid
inhibitor
assess
pseudoviru
model
result
similar
describ
overal
pseudoviru
mous
model
show
outcom
consist
authent
viru
mous
model
mous
therefor
uniqu
anim
model
evalu
vivo
efficaci
antimerscov
therapeut
vaccin
biolog
laboratori
lack
facil
research
advanc
skeptic
regard
pseudoviru
model
state
infect
pseudoviru
could
caus
patholog
chang
allay
doubt
combin
analysi
deem
necessari
studi
shown
figur
relev
pseudotyp
authent
viru
model
demonstr
show
manifest
infect
lung
main
target
merscov
infect
similar
authent
pseudoviru
model
case
infect
local
epitheli
cell
bronchi
dose
convers
pseudotyp
viru
authent
viru
calcul
indic
pseudoviru
mous
model
reliabl
use
evalu
effect
antivir
agent
howev
pseudoviru
repres
singlecycl
infect
without
replic
vivo
caus
patholog
chang
authent
merscov
infect
model
better
choic
studi
diseas
pathogenesi
summari
present
novel
ki
mous
model
mous
character
genet
stabil
suscept
infect
authent
pseudoti
merscov
clear
site
infect
present
diseas
symptom
respiratori
tract
cn
similar
clinic
patient
find
impli
uniqu
model
studi
human
pathogenesi
establish
pseudoviru
model
advantag
strong
signal
good
repeat
safeti
make
effici
authent
viru
model
evalu
antivir
agent
vaccin
typic
biolog
laboratori
